Roberto Iacovelli: Different results from 2 phase 3 studies on adjuvant IO for mRCC… what’s the reason?

Roberto Iacovelli, Associate Professor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome shared on X:

Quoting Roberto Iacovelli‘s post:

“Different results from 2 phase 3 studies (CM914 and KN564) on adjuvant IO for mRCC in similar but not equal populations at GU24. What’s the reason?

• Tx duration ( 6 vs 12 months)
• Population
• Therapy.”

Amol Akhade, Senior Consultant medical oncologist and hematooncologist at Reliance Hospitals, replied with:

“May be just by pure chance. We don’t know.

Duration difference of 6 months vs 12 months of adjuvant treatment should not be the major reason. We already know that from adjuvant trastuzumab studies in early breast cancer.

It is the 4 th option.

Luck by chance.”

Source: Roberto Iacovelli/X and Amol Akhade/X